ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,490,000 | -12.8% | 134,979 | -12.0% | 0.01% | -15.4% |
| Q3 2016 | $10,882,000 | +45.9% | 153,399 | +0.6% | 0.01% | +44.4% |
| Q2 2016 | $7,461,000 | -21.9% | 152,553 | +1.1% | 0.01% | -25.0% |
| Q1 2016 | $9,554,000 | -49.3% | 150,913 | -10.1% | 0.01% | -50.0% |
| Q4 2015 | $18,832,000 | +17.3% | 167,869 | +0.7% | 0.02% | +9.1% |
| Q3 2015 | $16,058,000 | +5.6% | 166,729 | +12.3% | 0.02% | +15.8% |
| Q2 2015 | $15,208,000 | +397.3% | 148,529 | +201.5% | 0.02% | +375.0% |
| Q1 2015 | $3,058,000 | +50.4% | 49,258 | +6.3% | 0.00% | +33.3% |
| Q4 2014 | $2,033,000 | -22.6% | 46,331 | -0.2% | 0.00% | -25.0% |
| Q3 2014 | $2,628,000 | +28.5% | 46,424 | +1.9% | 0.00% | +33.3% |
| Q2 2014 | $2,045,000 | +120.1% | 45,555 | +139.6% | 0.00% | +200.0% |
| Q1 2014 | $929,000 | – | 19,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |